Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07193563 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

A Phase 2 study of Social Anxiety Disorder (SAD), sponsored by Engrail Therapeutics.

Active
Registry status
Phase 2
Development phase
47
Enrollment target
20
Study locations

NCT07193563 is a Phase 2 study of Social Anxiety Disorder (SAD) that is active but no longer recruiting, run by Engrail Therapeutics. The registered enrollment target is 47 participants, below the 193-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07193563, a Phase 2 study of Social Anxiety Disorder (SAD), is active but no longer recruiting, sponsored by Engrail Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
47 participants
Enrollment target
20
Study locations

Study Summary

This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).

Conditions Studied

Social Anxiety Disorder (SAD)

Interventions

  • OTHER Placebo
  • DRUG ENX-102

Study Locations (20)

California

  • University of California - La Jolla
  • Neuroresearch Group - Los Angeles
  • Excell Research, Inc. - Oceanside
  • Anderson Clinical Research - Redlands
  • California Neuroscience Research, LLC - Sherman Oaks
  • Sunwise Clincial Research - Walnut Creek

Florida

  • CNS Health - Jacksonville
  • Clinical Neuroscience Solutions, Inc. - Orlando

Nevada

  • IMA Clinical Research - Las Vegas
  • Redbird Research - Las Vegas

New York

  • SPRI Clinical Trials, LLC - Brooklyn
  • Neurobehavioral Research, Inc. - Cedarhurst

Texas

  • Austin Clinical Trials Partners - Austin
  • Grayline Research Center - Wichita Falls

Arizona

  • IMA Clinical Research Phoenix - Phoenix

Colorado

  • Mountain View Clinical Research - Denver

Georgia

  • CenExel iResearch, LLC - Savannah

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2025-09-05
Est. Completion 2026-03
Phase Phase 2

Sponsor

Engrail Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07193563

The ClinicalTrials.gov registry entry for NCT07193563 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (76% lower). The listed sponsor is Engrail Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07193563 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Nevada.

Frequently Asked Questions

What is clinical trial NCT07193563 about?

NCT07193563 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder". This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).

What is the current status of trial NCT07193563?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2025-09-05. Estimated completion is 2026-03.

What conditions does trial NCT07193563 study?

This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).

What interventions are being tested in trial NCT07193563?

The interventions under investigation include: Placebo (OTHER), ENX-102 (DRUG).

Who is sponsoring clinical trial NCT07193563?

This trial is sponsored by Engrail Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07193563 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Social Anxiety Disorder (SAD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Social Anxiety Disorder (SAD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.